ITeos Therapeutics Newsroom

Wells Fargo Maintains ITeos Therapeutics(ITOS.US) With Buy Rating, Maintains Target Price $31

Futu NewsSep 17 17:32

ITeos Therapeutics Price Target Maintained With a $46.00/Share by HC Wainwright & Co.

Dow JonesSep 16 19:52

ITeos Therapeutics Analyst Ratings

BenzingaSep 16 19:42

Piper Sandler Maintains ITeos Therapeutics(ITOS.US) With Buy Rating, Maintains Target Price $36

Futu NewsSep 16 19:31

ITeos Therapeutics (ITOS) Receives a Buy From Piper Sandler

TipRanksSep 16 18:59

H.C. Wainwright Maintains ITeos Therapeutics(ITOS.US) With Buy Rating, Maintains Target Price $46

Futu NewsSep 16 18:31

Wedbush Raises Price Target on ITeos Therapeutics to $25 From $21, Keeps Outperform Rating

MT NewswiresSep 16 18:27

Wells Fargo Maintains ITeos Therapeutics(ITOS.US) With Buy Rating, Maintains Target Price $31

Futu NewsSep 14 21:32

Buy Rating Affirmed for ITeos Therapeutics Amid Promising Lung-201 Study Outcomes

TipRanksSep 14 20:58

J.P. Morgan Sticks to Its Buy Rating for ITeos Therapeutics (ITOS)

TipRanksAug 13 20:35

Wells Fargo Initiates Coverage On ITeos Therapeutics With Overweight Rating, Announces Price Target of $31

BenzingaAug 13 19:13

Wells Fargo Initiates ITeos Therapeutics(ITOS.US) With Buy Rating, Announces Target Price $31

Futu NewsAug 13 18:31

ITeos Therapeutics Analyst Ratings

BenzingaAug 12 22:40

JP Morgan Maintains Overweight on ITeos Therapeutics, Lowers Price Target to $24

BenzingaAug 12 22:39

Buy Rating Affirmed for ITeos Therapeutics on Strong Financials and Promising Pipeline Updates

TipRanksAug 9 19:19

HC Wainwright & Co. : The iTeos Therapeutics (ITOS.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $44.00 to $46.00.

Zhitong FinanceMay 13 19:21

ITeos Therapeutics Analyst Ratings

BenzingaMay 13 19:20

Wedbush Adjusts ITeos Therapeutics' Price Target to $21 From $18, Maintains Outperform Rating

MT NewswiresMay 11 00:23

Analysts Offer Insights on Healthcare Companies: ITeos Therapeutics (ITOS), Rani Therapeutics Holdings (RANI) and Vor Biopharma (VOR)

TipRanksMar 21 19:35

ITeos Therapeutics Analyst Ratings

BenzingaMar 12 21:10